Acer Therapeutics





Please Login or Register

Login|Register FREE

Stock Price
Open: 19.42
Prev. Close: 19.11
Low/Hi: 19.28 - 20.68
52-Week: 5.70 - 22.63
Equity: 49,443
90-Day Avg: 28,053
Todays Stock Vol: 72.5
20-Day (HV): 75.6
52-Week (HV): 101.8
Div. Yield:
Earnings: 11-May (Est.)
P/E Ratio:
Market Cap: 143.3 M
Short Int Pct: 0.0%
Pct Held By Inst.: 4.9%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ACER

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna(R), is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

ACER is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 13.4 B 1.33909E+10 3,455 3455 0.0% 0 7 K 7029
VXF Vanguard Extended Market ETF 5.8 B 5.8E+09 3,171 3171 0.0% 0 18 K 17982
WMCR Wilshire Micro-Cap ETF (based on the Wilshire US Micro-Cap Index) 27.9 M 2.79395E+07 801 801 0.03% 0.0003 8 K 8236

Wait, Before You Leave...

Want to Know More About ACER Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon